AAV with aMHC promoter driven FLPo
This AAV expresses FLPo driven by a cardiac aMHC promoter.
αMHC(0.4) promoter is derived from the murine α-MHC gene (alpha-myosin heavy chain) and drives cardiac-specific expression. The length of this promoter is 0.4 Kb. Based on studies in primary cardiomyocytes, this aMHC(0.4) promoter gives an expression level that is comparable to that of a CMV promoter.
FLPo is a codon-optimized version of FLPe that greatly increases the protein expression and the FRT recombination efficiency in mouse cells. FLP is a site-specific recombinase (SSR) from the _ integrase family which recognizes distinct 34 bp FRT sites. Like Cre/LoxP system, the FLP/FRT system has been widely used for gene expression and generating conditional knockout mice, mediated by the FLP/FRT system. Initial use of FLP in mammalian cells revealed inefficient recombinase activity due to thermal instability of the FLP protein. Subsequent screening for thermostable mutants resulted in the identification of FLPe which has a 4-fold higher recombination efficiency at 37oC than original FLP. However, the recombination efficiency of FLPe in cells remains very low relative to other recombinases because of its non-mammalian origin. FLPo is engineered by codon optimization of FLPe, and gives much higher expression and activity than FLPe.
Ready-to-use AAV expressing FLPo driven by a cardiac aMHC promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.